Want to see SE:SEDANA full AI Analyst Report?
SEDANA Stock Chart & Stats
kr10.72
-kr0.18(-1.05%)
At close: 4:00 PM EST
kr10.72
-kr0.18(-1.05%)
Day’s Range― - ―
52-Week Rangekr7.90 - kr18.32
Previous CloseN/A
Volume45.94K
Average Volume (3M)247.68K
Market Cap
kr858.27M
Enterprise Valuekr778.04
Total Cash (Recent Filing)kr51.79M
Total Debt (Recent Filing)kr7.32M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Oct 22, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding99,336,960
10 Day Avg. Volume186,290
30 Day Avg. Volume247,675
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)kr207.32M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and a large equity cushion materially reduce solvency risk and give management flexibility. Over the next 2–6 months this balance sheet supports continued investment in commercial expansion, absorbs cash burn without immediate refinancing, and preserves strategic optionality.
High Gross Margin On Product PortfolioA ~71% gross margin indicates favorable unit economics for Sedaconda and consumables. If revenue growth resumes, these margins support scalable operating profitability, buffer pricing pressure, and enable reinvestment in sales and clinical adoption to drive durable margin recovery over time.
Recurring Consumables-driven Revenue ModelConsumables tied to inhaled-sedation delivery create repeat revenue and customer stickiness with hospitals. This structural model supports predictable per-patient revenue streams, amplifies lifetime value of initial device adoption, and underpins sustainable growth as clinical protocols spread.
Bears Say
Sharp TTM Revenue ContractionA >30% decline in trailing revenue erodes scale benefits and slows clinical and commercial momentum. Over several months this undermines the path to cover fixed costs, delays breakeven, and makes it harder to leverage high gross margins into sustained operating profits without renewed adoption.
Persistent Negative Operating And Free Cash FlowConsistent cash burn and deeply negative FCF mean the company must rely on external funding or equity to sustain operations. Even with low debt this restricts capital allocation, risks dilution or financing constraints, and limits ability to scale commercial efforts or invest in R&D long-term.
Ongoing Operating Losses And Negative ROESustained operating and net losses indicate the business has yet to convert strong gross economics into profitability. Negative ROE reflects value destruction on capital employed; without durable revenue recovery, profitability metrics will continue to constrain reinvestment and shareholder returns.
Sedana Medical AB News
SEDANA FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was kr7.90 and its highest was kr18.32 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is kr858.27M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Oct 22, 2026 which is in 94 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Jul 17, 2026. The company reported -kr0.1 earnings per share for the quarter, missing the consensus estimate of -kr0.085 by -kr0.015.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is -0.09.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -kr0.1 in its last earnings report, missing expectations of -kr0.085. Following the earnings report the stock price went down -3.786%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in SE:SEDANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical tools designed for delivering volatile anesthetics, alongside the Sedaconda Syringe (a 50/60ml syringe) and a Sedaconda ACD starter kit. The company also provides FlurAbsorb and FlurAbsorb-S, active carbon filtration systems engineered to collect residual anesthetic gases discharged by ventilators. Complementing these are the FlurAbsorb accessory kit, which facilitates connecting ventilator exhausts and gas monitors to the filters, and the FlurAbsorb mount, used to secure the filter during anesthetic gas removal. Further offerings encompass the AMG-06 Gas Monitor, which enables ongoing, non-invasive sidestream measurement of carbon dioxide and anesthetic levels in inhaled and exhaled breaths. Additionally, they supply the Sedaconda Filling Adapter, a disposable tool for securely and simply transferring isoflurane from its container to a Sedaconda Syringe, as well as an array of supplemental items like DRYLINE II Water Traps, the WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Lines. Established in 1999, Sedana Medical AB (publ) maintains its corporate headquarters in Danderyd, Sweden.